

Valery Savchenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1527495/publications.pdf>

Version: 2024-02-01

109
papers

863
citations

759233

12
h-index

580821

25
g-index

150
all docs

150
docs citations

150
times ranked

1233
citing authors

#	ARTICLE	IF	CITATIONS
1	Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Diseaseâ€”A Phase II Study. <i>Stem Cells International</i> , 2012, 2012, 1-8.	2.5	98
2	Flt3-ligand production by human bone marrow stromal cells. <i>Leukemia</i> , 1996, 10, 1012-8.	7.2	82
3	Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. <i>Experimental Hematology</i> , 2003, 31, 1301-1309.	0.4	81
4	Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells. <i>Leukemia</i> , 2016, 30, 104-111.	7.2	54
5	Neutrophil microparticles modulate cytokine production by natural killer cells. <i>Cytokine</i> , 2014, 65, 126-129.	3.2	43
6	A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 801-808.	2.0	30
7	Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. <i>Biochemistry (Moscow)</i> , 2014, 79, 1363-1370.	1.5	22
8	Extracellular NAD ⁺ inhibits human neutrophil apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2014, 19, 581-593.	4.9	17
9	The CD68 protein as a potential target for leukaemia-reactive CTL. <i>Leukemia</i> , 2002, 16, 2019-2026.	7.2	14
10	Cytokine-mediated induction of MHC class II in human neutrophils is dependent on NADPH oxidase activity. <i>European Journal of Cell Biology</i> , 2015, 94, 67-70.	3.6	14
11	Stromal regulation of hemopoietic stem cells in long-term human bone marrow tissue cultures under the effect of parathyroid hormone. <i>Bulletin of Experimental Biology and Medicine</i> , 2006, 142, 527-530.	0.8	11
12	Analysis of multipotent mesenchymal stromal cells used for acute graftâ€”versusâ€”host disease prophylaxis. <i>European Journal of Haematology</i> , 2016, 96, 425-434.	2.2	11
13	Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 408-417.	1.3	11
14	Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFN γ Administration. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 230-234.	0.8	11
15	Bone Marrow Multipotent Mesenchymal Stromal Cells in Patients with Diffuse Large B-Cell Lymphoma. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 167, 150-153.	0.8	11
16	Defect of Stromal Microenvironment in Long Term Bone Marrow Cultures of Patients with Acute and Chronic Myelogenous Leukemias. <i>Leukemia and Lymphoma</i> , 1995, 19, 145-152.	1.3	10
17	Effect of priming of multipotent mesenchymal stromal cells with interferon γ on their immunomodulating properties. <i>Biochemistry (Moscow)</i> , 2017, 82, 1158-1168.	1.5	9
18	Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. <i>Stem Cells International</i> , 2018, 2018, 1-7.	2.5	9

#	ARTICLE	IF	CITATIONS
19	Clinical recommendations for the diagnosis and treatment of aplastic anemia (2019 edition). <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 208-226.	0.6	9
20	Vascular endothelium: target or victim of cytostatic therapy? This paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007, 85, 396-403.	1.4	8
21	Diadenosine diphosphate (Ap2A) delays neutrophil apoptosis via the adenosine A2A receptor and cAMP/PKA pathway. <i>Biochemistry and Cell Biology</i> , 2014, 92, 420-424.	2.0	8
22	The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cells. <i>European Journal of Haematology</i> , 2016, 97, 245-252.	2.2	8
23	Recombinant MHC tetramers for isolation of virus-specific CD8+ cells from healthy donors: Potential approach for cell therapy of posttransplant cytomegalovirus infection. <i>Biochemistry (Moscow)</i> , 2016, 81, 1371-1383.	1.5	8
24	A Single-center Experience in Splenic Diffuse Red Pulp Lymphoma Diagnosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S166-S169.	0.4	7
25	Level of Granzyme B-positive T-regulatory cells is a strong predictor biomarker of acute Graft-versus-host disease after day +30 after allo-HSCT. <i>Leukemia Research</i> , 2017, 54, 25-29.	0.8	7
26	IMMUNOBIOLOGY OF ACUTE GRAFT-VERSUS-HOST DISEASE. <i>Medical Immunology (Russia)</i> , 2016, 17, 499-516.	0.4	6
27	Clinical guidelines for cryoprecipitate transfusions. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 87-114.	0.6	6
28	Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 47-50.	1.0	5
29	Human Herpesvirus Type 8-positive Multicentric Castlemans Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S159-S165.	0.4	5
30	Outbreak of mass poisoning with anticoagulant rodenticides. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 174-189.	0.6	5
31	Identification of a novel allele HLA-C*12:138 in Russian patient by haplotype-specific sequence-based typing. <i>Tissue Antigens</i> , 2015, 85, 513-514.	1.0	4
32	Minimal residual disease and b-cell subpopulation monitoring in acute b-lymphoblastic leukaemia patients treated on rll-2016 protocol. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 192-205.	0.6	4
33	Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 23-29.	0.8	4
34	CDKN2A/p16INK4a DELETION IS NOT A POOR PROGNOSTIC FACTOR IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED ACCORDING TO PROTOCOL RALL-2009. <i>Oncogematologiya</i> , 2017, 12, 17-24.	0.3	4
35	Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 30-37.	0.8	4
36	MORPHOLOGICAL FEATURES OF TUMORS SUBSTRATE IN MULTIPLE MYELOMA PATIENTS COMPLICATED WITH PLASMACYTOMA. <i>Oncogematologiya</i> , 2018, 13, 73-81.	0.3	4

#	ARTICLE	IF	CITATIONS
37	HIGH-DOSE CHEMOTHERAPY FOR PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM. INTERIM RESULTS OF THE CNS-2015 PROTOCOL. <i>Gematologiya I Transfuziologiya</i> , 2019, 64, 447-461.	0.6	4
38	Reconstitution of T-cell-mediated immunity in patients after allogeneic stem cell transplantation. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 24-38.	0.6	4
39	Bloodstream infections in different stage of reconstitution after first allogeneic hematopoietic stem cell transplantation. <i>Oncogematologiya</i> , 2022, 17, 121-134.	0.3	4
40	Adhesion capacity and integrin expression by dendritic-like cells generated from acute myeloid leukemia blasts by calcium ionophore treatment. <i>Experimental Hematology</i> , 2004, 32, 563-570.	0.4	3
41	Long-term survival of donor bone marrow multipotent mesenchymal stromal cells implanted into the periosteum of patients with allogeneic graft failure. <i>International Journal of Hematology</i> , 2016, 104, 403-407.	1.6	3
42	Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry. <i>Blood</i> , 2020, 136, 41-42.	1.4	3
43	Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 14-22.	0.8	3
44	INFECTIONS ON DIFFERENT CHEMOTHERAPY CYCLES IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH ALL-2009 PROTOCOL. <i>Oncogematologiya</i> , 2017, 12, 31-40.	0.3	3
45	A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 370-385.	0.6	3
46	Implementation of allogeneic hematopoietic stem cell transplantation from unrelated donors from Russian and foreign registries. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 299-311.	0.6	3
47	Structure and prognostic significance of 13q14 deletion in chronic lymphocytic leukemia. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 75-89.	0.6	3
48	Determination of serum antiplatelet antibodies in patients with idiopathic thrombocytopenic purpura by ELISA. <i>Bulletin of Experimental Biology and Medicine</i> , 1989, 107, 359-361.	0.8	2
49	Delayed effects of long-term administration of granulocyte colony-stimulating factor to mice. <i>Bulletin of Experimental Biology and Medicine</i> , 2008, 145, 629-633.	0.8	2
50	Risk-adapted combined therapy with arsenic trioxide and all-trans-retinoic acid for de novo acute promyelocytic leukaemia. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 168-191.	0.6	2
51	Comparative assessment of efficacy and toxicity of R-DA-EPOCH and R-mNHL-BFM-90 induction courses in the treatment of patients with diffuse large B-cell lymphoma with poor prognostic factors in a randomized multicenter clinical trial "DLBCL-2015". <i>Oncogematologiya</i> , 2021, 16, 86-94.	0.3	2
52	MYD88 L265P Mutation Is a Possible Unfavorable Prognostic Factor in Patients with Diffuse B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5051-5051.	1.4	2
53	Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 110-117.	0.8	2
54	STUDY OF MINIMAL RESIDUAL DISEASE BY MULTICOLOR FLOW CYTOMETRY IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>Oncogematologiya</i> , 2017, 12, 62-69.	0.3	2

#	ARTICLE	IF	CITATIONS
55	EXPRESSION FEATURES OF ANTIGENS INVOLVED IN THE FORMATION OF IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Oncogematologiya</i> , 2018, 13, 103-114.	0.3	2
56	First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 77-81.	0.8	2
57	Infectious complications in patients with acute leukemia according to the duration of neutropenia. <i>Oncogematologiya</i> , 2018, 13, 55-62.	0.3	2
58	Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol). <i>Oncogematologiya</i> , 2018, 13, 10-24.	0.3	2
59	Next-generation sequencing-based molecular genetic profiling in adults with acute myeloid leukaemia. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 444-459.	0.6	2
60	Cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: clinical significance and definitions. <i>Transplantologiya</i> , 2022, 14, 210-225.	0.4	2
61	Genetic differences by platelet-specific antigens used for monitoring allomyelotransplant engraftment. <i>Bulletin of Experimental Biology and Medicine</i> , 2006, 141, 507-512.	0.8	1
62	Allele and haplotype frequencies of HLA-A, -B, -C, -DRB1, -DQB1 in Northern Ossetians from Vladikavkaz, Russia. <i>Human Immunology</i> , 2018, 79, 709-710.	2.4	1
63	Individual Differences of Multipotent Mesenchymal Stromal Cells Manifesting in during Interaction with Lymphocytes. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 165, 584-588.	0.8	1
64	Comparison of polymerase chain reaction and flow cytometry for measuring telomere length of human leukocytes. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 154-159.	0.5	1
65	Experience of haematological observatory ward during COVID-10 pandemic. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 8-19.	0.6	1
66	Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease. <i>Bulletin of Experimental Biology and Medicine</i> , 2021, 171, 553-558.	0.8	1
67	Next generation sequencing HLA-typing of recipients and donors of allogeneic haematopoietic stem cells. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 206-217.	0.6	1
68	Induction of Mixed Chimerism in Patients After Non-Myeloablative Stem Cell Transplantation (SCT) for High Risk Haematological Malignancies. <i>Hamatologie Und Bluttransfusion</i> , 2003, , 514-519.	0.0	1
69	Infectious complications in patients with multiple myeloma on first chemotherapy cycle. <i>Oncogematologiya</i> , 2018, 13, 63-75.	0.3	1
70	Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation. <i>Oncogematologiya</i> , 2019, 14, 76-82.	0.3	1
71	Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 51-56.	0.8	1
72	PROVISION OF CENTRAL VENOUS ACCESS DURING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>Gematologiya I Transfuziologiya</i> , 2019, 64, 396-411.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Clinical guidelines for cryosupernatant transfusions. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 351-359.	0.6	1
74	Contribution of social and demographic parameters to the long-term survival prognosis of chronic myeloid leukemia patients. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 346-361.	0.6	1
75	Minor histocompatibility antigens as targets for T-cell immunotherapy. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 322-345.	0.6	1
76	Combination of arsenicum trioxide and all trans retinoic acid in the treatment of relapsed acute promyelocytic leukemia. <i>Oncogematologiya</i> , 2015, 10, 8.	0.3	1
77	IMPACT OF HLA-DPB1 INCOMPATIBILITY ON THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM HLA-A-B-C*DRB1-DQB1-COMPATIBLE UNRELATED DONOR. <i>Oncogematologiya</i> , 2018, 13, 54-62.	0.3	1
78	Bone marrow MRI after autologous transplantation and the effect of residual tumor on progression-free survival of multiple myeloma patients. <i>Oncogematologiya</i> , 2019, 13, 46-53.	0.3	1
79	Infectious Complications in Multiple Myeloma Patients Receiving Various Antitumor Regimens. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2019, 12, 131-139.	0.4	1
80	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. <i>Gematologiya I Transfuziologiya</i> , 2019, 64, 35-48.	0.6	1
81	Oligoclonality and subpopulation structure of bone marrow T-cells in patients with aplastic anaemia. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 417-430.	0.6	1
82	First experience of allogeneic haematopoietic stem cell transplantation in patients with mantle cell lymphoma with a mutation in the <i>TP53</i> gene. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 483-500.	0.6	1
83	Regional hematology service registration system for the Russian Federation. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 610-621.	0.6	1
84	Evaluation of graft-versus-host disease based on measurement of HLA levels in the plasma of allogeneic bone marrow recipients. <i>Bulletin of Experimental Biology and Medicine</i> , 1995, 120, 1211-1213.	0.8	0
85	Production of granulocytic colony-stimulating factor in patients with chronic myeloleukemia. <i>Bulletin of Experimental Biology and Medicine</i> , 1998, 126, 724-727.	0.8	0
86	Analysis of Expression of Genes Involved in Immune Response Modulation in Silent Multipotent Mesenchymal Stromal Cells. <i>Bulletin of Experimental Biology and Medicine</i> , 2012, 153, 244-248.	0.8	0
87	Co-Culturing of Multipotent Mesenchymal Stromal Cells with Autological and Allogenic Lymphocytes. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 446-452.	0.8	0
88	Analysis of Bone Tissue Condition in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 169, 677-682.	0.8	0
89	Liá€Fraumeni syndrome in adult patients with acute lymphoblastic leukemia. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 763-769.	0.8	0
90	Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 753-762.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Multiple primary tumor of hematopoietic tissue: myeloid sarcoma in combination with mantle cell lymphoma. Case report. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 793-799.	0.8	0
92	The effect of cryopreservation on the parameters of mononuclear apoptosis during extracorporeal photopheresis. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 386-394.	0.6	0
93	Hepatitis B and Hepatitis C Co-Infection in Patients with Hematological Malignancies. <i>Blood</i> , 2011, 118, 2090-2090.	1.4	0
94	Detection of B-Cell Clonality in Bone Marrow Is Independent Predictor of Outcome in De Novo Diffuse Large B-Cell Lymphoma Patients Treated with High-Dose Chemotherapy. <i>Blood</i> , 2014, 124, 2967-2967.	1.4	0
95	Multiple Clonal TCR Gene Rearrangements Are Typical in Peripheral T-Cell Lymphoma Not Otherwise Specified. <i>Blood</i> , 2015, 126, 5036-5036.	1.4	0
96	Clonal CD57+ Cells in T-Cell Large Granular Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4904-4904.	1.4	0
97	SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT. <i>Oncogematologiya</i> , 2017, 12, 23-29.	0.3	0
98	Successful experience in treating primary cutaneous anaplastic large cell lymphoma occurring with common lesions of the skin and lung tissue. <i>Vestnik Dermatologii I Venerologii</i> , 2018, 94, 30-42.	0.6	0
99	Study of myelodysplastic features in patients with myelodysplastic syndromes by multicolor flow cytometry. <i>Oncogematologiya</i> , 2019, 13, 75-88.	0.3	0
100	Gray-zone lymphoma. Examples of rare clinical manifestation. <i>Terapevticheskii Arkhiv</i> , 2019, 91, 107-113.	0.8	0
101	Subpopulations of mobilized hematopoietic stem cells in patients with hematological malignances and donors: expression of CD38, HLA-DR and CD143. <i>Oncogematologiya</i> , 2019, 14, 48-58.	0.3	0
102	Detection of platelet-associated immunoglobulins and complement system components in patients with aplastic anemia and hemoblastosis. <i>Oncogematologiya</i> , 2019, 14, 38-51.	0.3	0
103	NELARABINE TREATMENT IN ADULT PATIENTS WITH REFRACTORY/ RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA: EXPERIENCE OF A SINGLE CENTRE. <i>Gematologiya I Transfuziologiya</i> , 2019, 64, 382-395.	0.6	0
104	Expression features of antigens involved in the formation of immunological synapse in splenic marginal zone lymphoma. <i>Oncogematologiya</i> , 2020, 15, 18-28.	0.3	0
105	The role of interleukin-3 and its receptor in acute leukemia pathogenesis. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 335-350.	0.6	0
106	Prognostic value of minimal residual disease before allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 539-555.	0.6	0
107	Use of eltrombopag in treatment programs for patients with aplastic anemia. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 29-40.	0.6	0
108	Differences in Protein Secretion by Multipotent Mesenchymal Stromal Cells Effective and Ineffective in the Prevention of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Bulletin of Experimental Biology and Medicine</i> , 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
109	Extracorporeal photopheresis in the treatment of chronic graft-versus-host-disease. Gematologiya i Transfuziologiya, 2022, 67, 202-215.	0.6	0